| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 8472 | 2015 |
| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6316 | 2015 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3889 | 2017 |
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3606 | 2019 |
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ... Journal of clinical oncology 28 (6), 1061-1068, 2010 | 3114 | 2010 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2231 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1925 | 2017 |
| Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ... The Lancet Oncology 19 (11), 1480-1492, 2018 | 1496 | 2018 |
| Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 930 | 2022 |
| Therapeutic vaccines for cancer: an overview of clinical trials I Melero, G Gaudernack, W Gerritsen, C Huber, G Parmiani, S Scholl, ... Nature reviews Clinical oncology 11 (9), 509-524, 2014 | 891 | 2014 |
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ... European journal of cancer 49 (6), 1287-1296, 2013 | 535 | 2013 |
| Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical … A Bex, P Mulders, M Jewett, J Wagstaff, JV Van Thienen, CU Blank, ... JAMA oncology 5 (2), 164-170, 2019 | 505 | 2019 |
| Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial A Birtle, M Johnson, J Chester, R Jones, D Dolling, RT Bryan, C Harris, ... The Lancet 395 (10232), 1268-1277, 2020 | 451 | 2020 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 429 | 2019 |
| Monocyte/macrophage infiltration in tumors: modulators of angiogenesis AEM Dirkx, MGA oude Egbrink, J Wagstaff, AW Griffioen Journal of leukocyte biology 80 (6), 1183-1196, 2006 | 423 | 2006 |
| Tumor Angiogenesis Modulates Leukocyte-Vessel Wall Interactions in Vivo by Reducing Endothelial Adhesion Molecule Expression AEM Dirkx, MGA oude Egbrink, MJE Kuijpers, ST van der Niet, ... Cancer research 63 (9), 2322-2329, 2003 | 341 | 2003 |
| Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies GC Jayson, J Zweit, A Jackson, C Mulatero, P Julyan, M Ranson, ... Journal of the National Cancer Institute 94 (19), 1484-1493, 2002 | 336 | 2002 |
| High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer S Rodenhuis, M Bontenbal, LVAM Beex, J Wagstaff, DJ Richel, MA Nooij, ... New England Journal of Medicine 349 (1), 7-16, 2003 | 331 | 2003 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ... Annals of Oncology 29 (5), 1235-1248, 2018 | 293 | 2018 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 287 | 2022 |
Robert HawkinsCancer Studies, University of Manchesterبريد إلكتروني تم التحقق منه على ics.manchester.ac.uk
